IXICO PLC - Asset Resilience Ratio
IXICO PLC (IXI) has an Asset Resilience Ratio of 1.79% as of March 2014. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IXI total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2013)
This chart shows how IXICO PLC's Asset Resilience Ratio has changed over time. See net assets of IXICO PLC for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down IXICO PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IXICO PLC stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX104.00K | 1.79% |
| Total Liquid Assets | GBX104.00K | 1.79% |
Asset Resilience Insights
- Limited Liquidity: IXICO PLC maintains only 1.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
IXICO PLC Industry Peers by Asset Resilience Ratio
Compare IXICO PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for IXICO PLC (2000–2013)
The table below shows the annual Asset Resilience Ratio data for IXICO PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2013-09-30 | 2.00% | GBX103.00K ≈ $12.53 |
GBX5.15 Million ≈ $626.97 |
-79.22pp |
| 2012-09-30 | 81.22% | GBX8.60 Million ≈ $1.05K |
GBX10.59 Million ≈ $1.29K |
+3.25pp |
| 2011-09-30 | 77.97% | GBX14.50 Million ≈ $1.76K |
GBX18.60 Million ≈ $2.26K |
-13.45pp |
| 2010-09-30 | 91.42% | GBX22.50 Million ≈ $2.74K |
GBX24.61 Million ≈ $2.99K |
+26.66pp |
| 2008-09-30 | 64.75% | GBX5.50 Million ≈ $669.19 |
GBX8.49 Million ≈ $1.03K |
-4.60pp |
| 2004-08-31 | 69.36% | GBX5.24 Million ≈ $637.19 |
GBX7.55 Million ≈ $918.74 |
-4.88pp |
| 2003-08-31 | 74.23% | GBX5.13 Million ≈ $624.29 |
GBX6.91 Million ≈ $840.99 |
+2.07pp |
| 2002-08-31 | 72.16% | GBX8.83 Million ≈ $1.07K |
GBX12.24 Million ≈ $1.49K |
-17.26pp |
| 2001-08-31 | 89.42% | GBX12.67 Million ≈ $1.54K |
GBX14.17 Million ≈ $1.72K |
+10.12pp |
| 2000-08-31 | 79.30% | GBX4.53 Million ≈ $550.80 |
GBX5.71 Million ≈ $694.62 |
-- |
About IXICO PLC
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imag… Read more